Sign up online today & collaborate
or click here to find out more
Last month, the FDA gave the pharmaceutical supply chain a further year to prepare for the DSCSA requirements, announcing a postponed deadline of November 2018 by when pharmaceutical manufacturers must include product identifiers on all prescription drug packages and cases.
The FDA announcement was widely anticipated and welcomed by key stakeholders across the pharmaceutical manufacturing sector as a necessary move for overall industry preparedness. Despite considerable resource being devoted to the initiative, widespread concern lingered in the industry regarding readiness for the November 2017 deadline.
PCI’s own clear response to the delayed enforcement reinforces its position as the market leading pharmaceutical outsourcing services provider and the strength of its ongoing commitment to Serialization.
Commenting on PCI’s commitment to the industry’s Serialization effort as market leader, PCI President and CEO Bill Mitchell said: “PCI is absolutely dedicated to maintaining our position at the forefront of the Serialization initiative and providing our clients with an industry-leading customer experience. We are committed to the Serialization industry initiative and are forcefully moving forward 100 percent with no plans to slow down our Serialization readiness despite the extended deadline to meet DSCSA requirements. We stand ready to support all our clients in providing safe and effective life-saving medicines for both the US market as well as that of the European Union and emerging global markets.”
PCI has been at the forefront of Serialization adoption and implementation, actively serializing commercial medicines for more than five years to a variety of established and emerging global commercial markets. This long-term strategy has ensured that PCI has second-to-none Serialization experience and expertise to support its clients.
In February, PCI announced a significant investment in expanding its global Serialization offering, tripling its capacity across its global supply network in advance of the DSCSA deadline. The investment includes providing best-in-class equipment; a flexible and seamless data exchange; and skilled staff teams with real Serialization expertise. PCI has grown its dedicated Serialization department to more than 30 associates and will realize Serialization readiness on over 80 individual lines.
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.
Chantel Richman/Carrie Lowe at Remarkable Content
T +44 (0) 1962 893 853/913